HC Wainwright Issues Negative Estimate for CRBP Earnings

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Research analysts at HC Wainwright decreased their Q2 2025 earnings estimates for shares of Corbus Pharmaceuticals in a research report issued on Wednesday, May 7th. HC Wainwright analyst A. Maldonado now anticipates that the biopharmaceutical company will post earnings of ($1.54) per share for the quarter, down from their previous forecast of ($1.02). HC Wainwright has a "Buy" rating and a $40.00 price objective on the stock. The consensus estimate for Corbus Pharmaceuticals' current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Corbus Pharmaceuticals' Q3 2025 earnings at ($1.56) EPS, Q4 2025 earnings at ($1.58) EPS, FY2025 earnings at ($6.07) EPS, FY2026 earnings at ($6.27) EPS, FY2027 earnings at ($6.97) EPS, FY2028 earnings at ($5.09) EPS and FY2029 earnings at ($2.90) EPS.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.26) by ($0.13).

Several other research firms have also recently commented on CRBP. Jefferies Financial Group lowered their price target on shares of Corbus Pharmaceuticals from $70.00 to $53.00 and set a "buy" rating on the stock in a report on Tuesday, March 11th. StockNews.com upgraded shares of Corbus Pharmaceuticals to a "sell" rating in a research note on Thursday, March 6th. B. Riley restated a "buy" rating on shares of Corbus Pharmaceuticals in a report on Wednesday, May 7th. Wedbush reissued an "outperform" rating and set a $51.00 target price on shares of Corbus Pharmaceuticals in a research report on Wednesday, March 12th. Finally, Oppenheimer decreased their price target on Corbus Pharmaceuticals from $60.00 to $56.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. One research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Corbus Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $50.88.

Corbus Pharmaceuticals Stock Down 2.9%

Shares of CRBP traded down $0.21 during trading hours on Friday, reaching $7.05. The company's stock had a trading volume of 77,803 shares, compared to its average volume of 358,354. The company has a 50 day moving average of $6.34 and a two-hundred day moving average of $10.68. The firm has a market cap of $86.27 million, a price-to-earnings ratio of -1.50 and a beta of 3.19. Corbus Pharmaceuticals has a 1-year low of $4.64 and a 1-year high of $61.90.

Hedge Funds Weigh In On Corbus Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Millennium Management LLC boosted its stake in Corbus Pharmaceuticals by 215.0% in the 4th quarter. Millennium Management LLC now owns 386,653 shares of the biopharmaceutical company's stock valued at $4,563,000 after buying an additional 263,902 shares in the last quarter. Orbimed Advisors LLC lifted its holdings in Corbus Pharmaceuticals by 28.5% in the fourth quarter. Orbimed Advisors LLC now owns 1,172,287 shares of the biopharmaceutical company's stock valued at $13,833,000 after buying an additional 259,735 shares during the period. Altium Capital Management LLC lifted its stake in shares of Corbus Pharmaceuticals by 97.4% in the 4th quarter. Altium Capital Management LLC now owns 385,000 shares of the biopharmaceutical company's stock valued at $4,543,000 after purchasing an additional 190,000 shares during the period. Prosight Management LP boosted its position in shares of Corbus Pharmaceuticals by 107.7% in the 4th quarter. Prosight Management LP now owns 270,000 shares of the biopharmaceutical company's stock worth $3,186,000 after purchasing an additional 140,000 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Corbus Pharmaceuticals by 769.4% during the fourth quarter. Renaissance Technologies LLC now owns 139,100 shares of the biopharmaceutical company's stock worth $1,641,000 after purchasing an additional 123,100 shares during the period. 64.64% of the stock is owned by institutional investors.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.